1. MATCH Results: Implications for the Internist
Helmi L. Lutsep, MD 
The American Journal of Medicine 
Volume 119, Issue 6, Pages 526.e1-526.e7 (June 2006)
DOI: /j.amjmed
Copyright © 2006 Elsevier Inc. Terms and Conditions

2. Figure 1
Kaplan-Meier curves for cumulative rates of primary end point events. (Reprinted with permission from Elsevier [The Lancet, 2004, Vol 364, pp 331–337].15)
The American Journal of Medicine  , 526.e1-526.e7DOI: ( /j.amjmed )
Copyright © 2006 Elsevier Inc. Terms and Conditions

3. Figure 2
Rates and relative risks of primary end point event in prespecified subgroups. Although trends in favor of clopidogrel + aspirin were seen, no subgroup revealed a significant difference for the 2 treatment groups. IS = ischemic stroke; TIA = transient ischemic attack; MI = myocardial infarction; PAD = peripheral arterial disease; CI= confidence interval. (Reprinted with permission from Elsevier [The Lancet, 2004, Vol 364, pp 331–337.]15)
The American Journal of Medicine  , 526.e1-526.e7DOI: ( /j.amjmed )
Copyright © 2006 Elsevier Inc. Terms and Conditions

4. Figure 3
Kaplan-Meier curves for cumulative rates of primary intracranial hemorrhage. (Reprinted with permission from Elsevier [The Lancet, 2004, Vol 364, pp 331–337].15)
The American Journal of Medicine  , 526.e1-526.e7DOI: ( /j.amjmed )
Copyright © 2006 Elsevier Inc. Terms and Conditions

5. Figure 4 Treatment algorithm for secondary prevention of stroke.17,18
The American Journal of Medicine  , 526.e1-526.e7DOI: ( /j.amjmed )
Copyright © 2006 Elsevier Inc. Terms and Conditions